Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has announced the listing of new contract months for stock futures and stock options starting November 25, 2025, following the company’s listing change on the KOSPI market after its corporate spin-off.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Notice on New Listing of Stock Futures and Options (Listing of New Contract Months for Stock Futures/Options Following Listing Change on KOSPI Market)
- Listing Background: Change of listing for Samsung Biologics on the KOSPI market following its corporate spin-off (November 24, 2025)
- Newly Listed Contract Months:
- Stock Futures: Dec 2025, Jan 2026, Feb 2026, Mar 2026, Jun 2026, Sep 2026
- Stock Options: Dec 2025, Jan 2026, Feb 2026, Mar 2026, Jun 2026, Sep 2026
- Trading Start Date: November 25, 2025 (Tuesday / Trading day following KOSPI listing change)
- Final Trading Day: Second Thursday of the respective contract month
- Other Reference Items: Order quantity limit is 1,000 contracts, remaining same as before.
- Governing Rules: Articles 22, 27, 28, and 37 of the Derivatives Market Business Regulations, and Articles 8, 11, 13, and 19 of its Enforcement Rules.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Trading Commencement of New Stock Futures and Options Contract Months
This disclosure notifies the market regarding the schedule for listing new contract months of stock futures and options on the derivatives market following the company’s listing change on the KOSPI market post-spin-off.
Checking whether trading in these derivatives opens smoothly on the trading start date (November 25, 2025) and verifying contract terms such as final trading days is crucial for understanding derivative instruments linked to the underlying equity.
Relevant details can be verified in Korea Exchange (KRX) derivatives market notices and official market announcements.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
